MedTrace Logo

BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM

NCT02871622 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2016-08-18

No results posted yet for this study

Summary

Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data collection. Major adverse cardiac events (MACE) results at 9 months will be compared to the results obtained from the BioMatrix FlexTM arm of the LEADERS trial.

Conditions

Interventions

DEVICE

BioMatrix AlphaTM

Cobalt Chromium BA9 TM drug-eluting stent

Sponsors & Collaborators

  • European Cardiovascular Research Center

    collaborator NETWORK

  • Biosensors Europe SA

    lead INDUSTRY

Principal Investigators

  • Ian BA Menown, Dr · Craigavon Cardiac Centre

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-12-31
Completion
2019-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02871622 on ClinicalTrials.gov